Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of interleukin-12

A new application technology of interleukin, which is applied in the new application field of interleukin-12, can solve the problems of rejection, regulation disorder, testosterone propionate masculine side effects and other problems, and achieve good results

Inactive Publication Date: 2011-05-25
广州市恺泰生物科技有限公司
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current recommended treatment methods have more or less unsatisfactory aspects: ①Such as hematopoietic stem cell transplantation and bone marrow transplantation, it is difficult to find a corresponding HLA-matched donor, the cost is high, and adverse reactions such as rejection occur reaction
② The total effective rate of immunosuppressive therapy reaches one-third, and the recurrence rate reaches 20-30% among those who are effective, and the complication rate is 10-15%, and the cost is also high
③Androgen therapy. Although androgen is the first-line drug for the treatment of non-severe aplastic anemia (NSAA), the side effects of testosterone propionate are relatively masculine, such as acne, increased hair, thicker voice, amenorrhea in women, and accelerated bone maturation in children. Early fusion of epiphyses, etc.
Prolonged use of the regulation of pituitary gonadotropins causes regulatory disturbances

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of interleukin-12
  • New application of interleukin-12
  • New application of interleukin-12

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0041] Expression of Apoptotic Rate of HSC in Mouse Bone Marrow Nucleated Cells Irradiated by Radiation

[0042] Purpose of the experiment: To observe the preventive and therapeutic effects of IL-12 on radiation-damaged cells

[0043] Experimental method: SPF grade Kunming mice were selected and irradiated with 4Gy by a linear accelerator. They were administered once 24 hours before radiation and 24 hours after radiation. They were sacrificed 4 days after irradiation, and the apoptosis rate of bone marrow HSC was detected. APC marked HSC, AnnexinⅤPE was the detection index of apoptosis.

[0044] (1) Preparation of bone marrow nucleated cells

[0045] BALB / c mice were killed by cervical dislocation, and bilateral femurs were taken under aseptic conditions, cultured in RPMI164 complete culture medium (with 10% fetal bovine serum added), and the bone marrow was obtained by repeatedly blowing and blowing with a syringe, and separated by lymphocyte separation medium Mononuclear c...

Embodiment 3

[0057] Preventive and Protective Effects of IL-12 on Physical Damage of Hematopoietic System Caused by Radiation

[0058] ①Protective effect of rmIL-12 on lethal dose radiation injury in mice

[0059] Test animals: 60 SPF grade BALB / c mice, 20-22 g, single sex.

[0060] Drugs used in the test: the negative control is sterilized normal saline, and the recombinant mouse interleukin-12 (rmIL-12) is the product of peprotech company.

[0061]

[0062] The administration methods were all subcutaneous administration, and the administration volume was 150 μl. The radiation method is whole body radiation, and the dose is 10Gy.

[0063] Observation indicators: Survival rate of mice 4 weeks after radiation.

[0064] Experimental results: All the mice in the first group died, 15 survived in the second group, and 13 survived in the third group.

[0065] Conclusion: Administration of rmIL-12 before and after lethal dose radiation can significantly improve the survival rate of mice. ...

Embodiment 4

[0090] A test of the preventive and protective effects of rhIL-12 on the damage of the hematopoietic system caused by physical and chemical drugs.

[0091] Experimental plan: Use physical and chemical methods to injure the hematopoietic system of experimental mice, make a model of aplastic anemia, and then study the therapeutic effect of IL-12 on it.

[0092] experimental method:

[0093] Divide 100 Kunming rats into two groups. One group is the normal control group with 15 rats, 8 females and 7 males; the other group is the model group with 42 females and 43 males, totaling 85 rats. The model group was irradiated with 4Gy from a linear accelerator. On the fourth day, cyclophosphamide and chloramphenicol were administered for chemotherapy. The administration was continued for 3 days, once a day, and blood was collected on the 8th day for hemogram analysis. On the 16th day, the above combined regimen of radiation and chemotherapy was continued once again. In the model group, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Interleukin-12 (IL-12) can enhance the apoptosis resistant effect of hematopoietic stem cells during physical and chemical injury through IL-12 receptors expressed on the hematopoietic stem cells, and meanwhile, can promote the repair effect of organisms during hematopoietic system damage caused by radiation injury resulted from Co60 (gamma rays) and linear accelerators (X rays), chemical injury resulted from cyclophosphamide and chloromycetin, and the like. The IL-12 has good application prospect in preparation of medicaments for treating aplastic anemia.

Description

technical field [0001] The present invention relates to a new application of interleukin-12 (interleukin-12, IL-12), especially the application of the drug prepared by its recombinant product produced by genetic engineering in the treatment of aplastic anemia. Background technique [0002] Aplastic anemia (aplastie anemia), referred to as aplastic anemia, is a group of bone marrow stem cell failure or abnormality caused by chemical, physical, biological factors, drugs and unknown reasons, and a group of syndromes mainly manifested by pancytopenia in the blood. Clinically, it usually presents with anemia, hemorrhage, and infection. [0003] The cause and pathogenesis of aplastic anemia are not very clear yet. Some drugs, chemicals and viruses have been epidemiologically confirmed to be related to the onset of aplastic anemia. For example, the drugs include various antineoplastic drugs, chloramphenicol etc.; chemicals such as benzene and its derivatives; hepatitis B virus can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/20A61P7/06
Inventor 张宜俊夏书奇王翠玲王增松李文棠郭桂铃牛丽红罗群芳李平谢飞群宋阳
Owner 广州市恺泰生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com